Hyper-Eosinophilic Syndrome with Myocarditis after Inactivated SARS-CoV-2 Vaccination-A Case Study
Current Drug Safety, ISSN: 1574-8863, Vol: 18, Issue: 1, Page: 103-106
2023
- 7Citations
- 29Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations7
- Citation Indexes7
- CrossRef3
- Captures29
- Readers29
- 29
- Mentions1
- News Mentions1
- News1
Most Recent News
Hyper-eosinophilic syndrome with myocarditis after inactivated SARS-CoV-2 vaccination – a case study
This article was originally published here Curr Drug Saf. 2022 May 9. doi: 10.2174/1574886317666220509165317. Online ahead of print. ABSTRACT INTRODUCTION: COVID-19 vaccine induced serious adverse
Article Description
Introduction: COVID-19 vaccine-induced serious adverse reactions are rare. Hyper-eosinophilia syndrome with myocarditis has not been reported earlier following BBV152 vaccine administration. Case Presentation: A young man without any co-morbidities presented with persistent periorbital swelling along with itchy swelling over fingers, resting tachycardia, and exertional breathlessness following the first dose of an inactivated SARS-CoV-2 vaccine (BBV152, COVAXIN). On inves-tigation, the patient had elevated blood eosinophils (maximum 21.5% with an absolute eosinophil count of 2767/mm) and myocarditis (Lake Louise Criteria). He was successfully treated with ster-oids and supportive treatment. Conclusion: This is the first reported case of hyper-eosinophilia syndrome after COVAXIN ad-ministration. Prior history of the allergic disease may be a predisposing factor in this case. Hyper-eosinophilia can present with variable symptoms. In the current case, myocarditis was present with persistent resting tachycardia and dyspnea. Steroid and antiallergic drugs may be successful for the treatment of vaccine-induced hyper-eosinophilia with myocarditis. Increased vigilance is needed for such adverse events.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85130560896&origin=inward; http://dx.doi.org/10.2174/1574886317666220509165317; http://www.ncbi.nlm.nih.gov/pubmed/35579125; https://www.eurekaselect.com/204462/article; https://dx.doi.org/10.2174/1574886317666220509165317; https://www.eurekaselect.com/article/123251
Bentham Science Publishers Ltd.
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know